Nine signals worth checking before you trust an online GLP‑1 offer

A strong telehealth experience can be fast. Speed is not the problem; missing accountability is. The FDA’s current guidance gives consumers a useful set of clues when evaluating GLP-1 offers online.

Red flag: no real prescription step

Prescription medication should involve a licensed clinician and an appropriate evaluation. Be wary of sites that sell a prescription drug without requiring a prescription, hide who provides clinical care, or imply that answering a marketing quiz guarantees treatment.

Red flag: “research use” sold as human treatment

The FDA warns against products marked “for research purposes” or “not for human consumption” that are then sold for people. It also states that retatrutide and cagrilintide cannot be used in compounding under federal law. A professional-looking bottle or social account does not replace an approved or lawful care pathway.

Red flag: the pharmacy stays anonymous

A program may assign a pharmacy after clinical review, but it should be able to identify the licensed dispenser before a product is used. If support cannot tell you who filled the prescription or how to reach the pharmacy, stop and get clarity.

Red flag: outcome claims without context

Testimonials and dramatic weight-loss figures can omit time, dose, medical criteria, discontinuations, lifestyle support, side effects, and who was paid. The FTC’s Health Products Compliance Guidance explains that health advertising needs competent and reliable scientific evidence and that disclosures cannot cure a misleading headline.

Red flag: a tiny price with a large commitment

Find the amount due today and the normal renewal. Look for automatic renewals, dose-based increases, long prepaid terms, and what happens if the clinician does not prescribe the pictured route. Save a copy of the terms you accepted.

Green flags are specific

Look for a named clinical entity, a clear prescription process, pharmacy identification, an itemized ordinary price, reachable clinical and pharmacy support, transparent cancellation rules, and a correction-friendly posture. No single badge proves quality. A set of accountable facts is more useful.

If a medication or shipment seems suspect, contact the prescriber and dispensing pharmacy. FDA guidance also explains how to report suspected illegal sales and adverse events. GLP.directory does not authenticate products or replace that reporting channel.

The full nine-point screen

1. No meaningful prescription process. A marketing questionnaire is presented as if it guarantees treatment.
2. No reachable licensed clinician. Customer service exists, but post-delivery clinical questions have no clear owner.
3. The pharmacy is hidden or questionable. The label, address, and license cannot be reconciled.
4. “Research use” becomes consumer treatment. Products marked not for human consumption are sold as a care pathway.
5. A compounded product is called FDA approved, generic, or identical. Those descriptions erase a material regulatory distinction.
6. The price seems complete but omits renewal or commitment. The small monthly figure is prepaid, introductory, or excludes medication.
7. Outcomes sound guaranteed. Testimonials or percentages appear without conditions, evidence, or a clear typical-results context.
8. The shipment cannot be questioned. Damaged packaging, warm delivery, changed appearance, or missing instructions receives only a scripted response.
9. The business identities do not line up. The brand, medical group, prescriber, pharmacy, billing descriptor, and terms point to unexplained entities.

One red flag is a question; several are a pattern

A changed pharmacy or a low introductory price is not automatically improper. The issue is whether the company can explain the change, identify the responsible licensed entities, and give the patient enough information to make a safe and informed decision. Evidence matters more than polish.

Use the pharmacy checklist for dispensing questions and the true-cost guide for commercial terms.

---

Sources: FDA, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss”; FTC, “Health Products Compliance Guidance.” Checked September 10, 2026.

Source ledger

Primary and first-party sources

3 checked

1. U.S. Food and Drug Administrationfda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss ↗
2. U.S. Food and Drug Administrationfda.gov/consumers/consumer-updates/how-buy-medicines-safely-online-pharmacy ↗
3. Federal Trade Commissionftc.gov/business-guidance/resources/health-products-compliance-guidance ↗

These links support specific facts; inclusion is not an endorsement. Terms can change after the review date.